EMPLICURE HAS FORMED NOMINATION COMMITTEEEmplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2024 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter. The Nomination Committee for the 2024 AGM is:
- Per Collén (for TomEqt Private AB)
- Sten Wranne (for Johan Wieslander AB)
- Thomas Lundqvist
The Nomination Committee represents 72.9% of the votes in Emplicure.
The Nomination Committee shall consist of three representatives nominated by the three largest shareholders per the last business day in September. The chairperson of the Board may be invited to the meetings of the Nomination Committee. The chairperson of the Nomination Committee shall be the member appointed by the largest shareholder in terms of voting rights, unless the Nomination Committee unanimously appoints another representative as the chairperson of the Nomination Committee.
The Nomination Committee's tasks are to submit the following proposals to the Annual General Meeting:
- Election of Board of Directors (BoD)
- Election of av Chairman of the Board
- Resolution regarding number of auditors and auditor election
- Remunerations for the BoD and the auditors
- Principles that shall apply to the composition and work of the nomination committee for the next AGM
Primary contact for the Nomination Committee Proposals by shareholders to the Nomination Committee may be submitted to the Chairman of the Board of Emplicure AB, Gisela Sitbon ([email protected]).
Certified Adviser Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.
The following documents can be retrieved from beQuoted
PM-Emplicure Nomination Committee 2024 ENG.pdf Emplicure uses patented bioceramic technology to develop innovative and effective products to help consumers and patients live better lives. Our consumer division makes tiny, long-lasting and flavorful nicotine pouches that can be an alternative to smoking. Our pharmaceutical division develops safer and tamper-resistant treatments for pain. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
|